English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Rivastigmine, an Anti-Alzheimer’s drug suffer from a major limitation of sever GI adverse events such as nausea, vomiting, diarrhea, loss of appetite, weight loss and increase dosing frequency [1]. The present work aim at design, optimization and development of rivastigmine once a day controlled release formulation to minimize the above limitation and increase patient’s compliance. Based on the target in-vitro release profile derived from pharmacokinetic simulation [2], a once a day matrix tablet with the simulated dose was developed. The simple direct compression process was followed as a manufacturing process, the percentage of Polymer HPMC K100M, Polyethylene oxide (PEO WSR303) and insoluble excipients microcrystalline cellulose used in the formulation were optimized using 23 full factorial design. The formulations were then evaluated for the physical characteristics of blend, tablets, swelling index, percentage of erosion, drug release and release rate kinetic. The quadratic model was suggested, contour and 3D graphs were generated. The optimized formulation was subjected to stability studies. The final optimized formulation showed a comparative release profile similar to that the desired in-vitro target release profile, which followed zero order release kinetics and a stable formulation. Keywords: Controlled Release Formulation, Rivastigmine Tartarate , Anti-Alzheimer’s drug, HPMC K100M, Polyethylene oxide (PEO WSR303)

DESIGN, OPTIMIZATION, DEVELOPMENT AND EVALUATION OF ONCE A DAY CONTROLLED RELEASE FORMULATION OF RIVASTIGMINE TARTARATE